Evidence map›Paper›PMID 39066957›Full record

ArticleBiotechnology letters2024

Plant production of recombinant antigens containing the receptor binding domain (RBD) of two SARS-CoV-2 variants.

Flavia Fagiani, Rachele Frigerio, Anna Maria Salzano, Andrea Scaloni, Carla Marusic, Marcello Donini

Abstract read
PubMed Publisher
In one paragraph

Article in Biotechnology letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Flavia Fagiani *Laboratory of Biotechnology, ENEA Research Center Casaccia, 00123, Rome, Italy.
Rachele Frigerio *Laboratory of Biotechnology, ENEA Research Center Casaccia, 00123, Rome, Italy.
Anna Maria SalzanoProteomics, Metabolomics & Mass Spectrometry Laboratory, ISPAAM, National Research Council, 80055, Portici, Italy.
Andrea ScaloniProteomics, Metabolomics & Mass Spectrometry Laboratory, ISPAAM, National Research Council, 80055, Portici, Italy.
Carla MarusicLaboratory of Biotechnology, ENEA Research Center Casaccia, 00123, Rome, Italy. Carla.marusic@enea.it.
Marcello DoniniLaboratory of Biotechnology, ENEA Research Center Casaccia, 00123, Rome, Italy. marcello.donini@enea.it.ORCID http://orcid.org/0000-0001-9183-0728

Funding

Ministero dell'Istruzione, dell'Università e della Ricerca 1554/2022Ministero dell'Istruzione, dell'Università e della Ricerca CUP I83C21000240001Ministero dell'Istruzione, dell'Università e della Ricerca PE00000007
6 · The paper itself

Abstract

objectivesThe aim of this work was to rapidly produce in plats two recombinant antigens (RBDw-Fc and RBDo-Fc) containing the receptor binding domain (RBD) of the spike (S) protein from SARS-CoV-2 variants Wuhan and Omicron as fusion proteins to the Fc portion of a murine IgG2a antibody constant region (Fc).

resultsThe two recombinant antigens were expressed in Nicotiana benthamiana plants, engineered to avoid the addition of N-linked plant-typical sugars, through vacuum agroinfiltration and showed comparable purification yields (about 35 mg/kg leaf fresh weight).

conclusionsTheir Western blotting and Coomassie staining evidenced the occurrence of major in planta proteolysis in the region between the RBD and Fc, which was particularly evident in RBDw-Fc, the only antigen bearing the HRV 3C cysteine protease recognition site. The two RBD N-linked glycosylation sites showed very homogeneous profiles free from plant-typical sugars, with the most abundant glycoform represented by the complex sugar GlcNAc

Indexed as

NicotianaSARS-CoV-2Spike Glycoprotein, CoronavirusAnimalsAntibodies, NeutralizingAntibodies, ViralAntigens, ViralCOVID-19HumansMicePlants, Genetically ModifiedProtein DomainsRecombinant Fusion ProteinsRecombinant ProteinsAntibodies, NeutralizingAntibodies, ViralAntigens, ViralRecombinant Fusion ProteinsRecombinant ProteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID19Molecular farmingProteolytic degradationSARS-CoV-2Transient expression

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.